Ensuring Safer Sterilization

NanoGuard’s Cold Plasma technology is an innovative solution for low-temperature medical device sterilization.

Kills harmful
pathogens
0 %
Residue-free
0 %
additional
chemicals required
0

ABOUT US

Our Technology

Since 2014, NanoGuard Technologies has been at the forefront of innovative cold plasma solutions in the agricultural and medical industries. NanoGuard holds 4 global patents for HVACP technology in 28 countries.

We are at the forefront of developing novel sterilization methods that address the evolving needs of the industry. Our technology achieves a 6.0-log reduction of Bacillus atrophaeus spore strips, the same biological indicator used to validate ethylene oxide sterilization in the industry.

Our Four Key Patents

Mycotoxin and microbial reduction – granted globally, with a limited non-exclusive license held by Bunge.

Virus treatment – granted in the US and EU, with global patents pending.

Plasma generator design – granted in the US and EU, with global patents pending.

Cost-effective treatment improvements – filed as a US provisional patent.

"Ethylene oxide, one of the most potent cancer-causing chemicals" – EPA

Our Mission

At NanoGuard, our mission is to provide safe and reliable sterilization solutions that help create healthier environments for everyone.

WHY CHOOSE US

High market growth and stricter regulations in medical device sterilization present a unique opportunity for NanoGuard

20 billion articles are sterilized annually in the U.S.

EPA regulations are forcing change.

Projected growth of 10.7% through 2030.

Compliance measures to cost the industry $220M in CapEx and $68M in OpEx.

Ethylene oxide sterilizes 50% of medical devices.

$1.70B U.S. market share.

BLOGS

Stay up to date with us

etorsd
In the medical device sterilization services industry,...

NEWSLETTER

Stay Informed with our Newsletter

Subscribe to our newsletter and be the first to receive updates on cutting-edge sterilization technologies,from NanoGuard Technologies.